10 Low Risk High Reward Stocks Set to Triple by 2030

8. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 15

Potential upside: 339.92%

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotech company focused on changing cancer treatment with its new product, ANKTIVA. It is working on hard-to-treat cancers, especially bladder cancer, with good results so far. Since ANKTIVA got FDA approval and hit the U.S. market in May 2024, over 200 million people now have insurance coverage for it, with both public and private insurers on board.

ImmunityBio is doing well on the financial side, as in Q3 2024, it made $6.0 million in product revenue, six times more than last quarter and outperforming analysts’ predictions. Starting January 2025, ANKTIVA has a permanent J-code, making it easier for Medicare and VA patients to get covered. ImmunityBio, Inc. (NASDAQ:IBRX) is also expanding globally, having applied for approval in the UK’s MHRA last November and planning for an EMA in the EU soon.

Still, ImmunityBio isn’t profitable yet as it lost $85.7 million in Q3, with rising R&D and SG&A costs driven by the company’s growth. However, investors are still hopeful, as in April 2025, ImmunityBio, Inc. (NASDAQ:IBRX) secured a $75 million equity financing deal from an institutional investor. This would not only back the ongoing pipeline but could potentially reach $165 million if all warrants are exercised.

With a strong scientific front and strategic funding behind it, ImmunityBio (NASDAQ:IBRX) has set itself up as one of the best low risk stock options for investors.